ENTRY       D11243                      Drug
NAME        Ublituximab (USAN/INN);
            Briumvi (TN)
PRODUCT     BRIUMVI (TG Therapeutics)
FORMULA     C6418H9866N1702O2006S48
EXACT_MASS  144412.8918
MOL_WEIGHT  144502.3284
SEQUENCE    (Heavy chain)
            QAYLQQSGAE LVRPGASVKM SCKASGYTFT SYNMHWVKQT PRQGLEWIGG IYPGNGDTSY
            NQKFKGKATL TVGKSSSTAY MQLSSLTSED SAVYFCARYD YNYAMDYWGQ GTSVTVSSAS
            TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL
            YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS
            VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST
            YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSRDELT
            KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ
            GNVFSCSVMH EALHNHYTQK SLSLSPGK
            (Light chain)
            QIVLSQSPAI LSASPGEKVT MTCRASSSVS YMHWYQQKPG SSPKPWIYAT SNLASGVPAR
            FSGSGSGTSY SFTISRVEAE DAATYYCQQW TFNPPTFGGG TRLEIKRTVA APSVFIFPPS
            DEQLKSGTAS VVCLLNNFYP REAKVQWKVD NALQSGNSQE SVTEQDSKDS TYSLSSTLTL
            SKADYEKHKV YACEVTHQGL SSPVTKSFNR GEC
            (Disulfide bridge: H22-H96, H145-H201, H221-L213, H227-H'227, H230-H'230, H262-H322, H368-H426, H'22-H'96, H'145-H'201, H'221-L'213, H'262-H'322, H'368-H'426, L23-L87, L133-L193, L'23-L'87, L'133-L'193)
  TYPE      Peptide
REMARK      ATC code: L04AA57
            Product: D11243<US>
EFFICACY    Antineoplastic, Anti-CD20 antibody
  DISEASE   Multiple sclerosis [DS:H01490]
  TYPE      Monoclonal antibody
COMMENT     Treatment of cancer, autoimmune disorders
TARGET      CD20 [HSA:931] [KO:K06466]
  PATHWAY   hsa04640(931)  Hematopoietic cell lineage
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AA Selective immunosuppressants
                 L04AA57 Ublituximab
                  D11243  Ublituximab (USAN/INN) &lt;US&gt;
            USP drug classification [BR:br08302]
             Central Nervous System Agents
              Multiple Sclerosis Agents
               Ublituximab
                D11243  Ublituximab (USAN/INN)
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Other cell surface molecules
               CD molecules
                CD20
                 D11243  Ublituximab (USAN/INN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11243
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11243
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11243
DBLINKS     CAS: 1174014-05-1
            PubChem: 384585221
///
